BMY
BRISTOL MYERS SQUIBB CO
NYSE · Healthcare · Drug Manufacturers - General · US
$58.83
−1.54%Oct 19, 2026, 17:30 UTC
BRISTOL MYERS SQUIBB CO reported 96% MICROSOFT CORP 365 Copilot adoption across its approximately 30,000-person workforce.
Source:Oct 19, 2026, 10:59 UTC
BRISTOL MYERS SQUIBB CO announced that it plans to showcase cancer modalities and its solid-tumor portfolio at ESMO 2026.
Source:Oct 17, 2026, 21:45 UTC
AbbVie Inc., BRISTOL MYERS SQUIBB CO and Boehringer Ingelheim moved to intervene in the lawsuit over the 340B rebate pilot.
Source:Oct 14, 2026, 22:45 UTC
The listed top gainers included Perrigo, up 3.77%; GILEAD SCIENCES, INC., up 3.8%; Kroger, up 3.87%; BRISTOL MYERS SQUIBB CO, up 4.61%; and UNITEDHEALTH GROUP INC, up 4.73%.
Source:Oct 13, 2026, 18:40 UTC
BRISTOL MYERS SQUIBB CO reported mixed Phase III trial results for admilparant in idiopathic pulmonary fibrosis and positive results for RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors.
Source:Oct 12, 2026, 22:46 UTC
BRISTOL MYERS SQUIBB CO shares closed at $57.60, down 2.58% from the previous close.
Source:Oct 12, 2026, 17:42 UTC
BRISTOL MYERS SQUIBB CO shares fell 3% to $57.39.
Source:Oct 12, 2026, 16:59 UTC
Contineum Therapeutics, Inc. shares plunged Monday after mixed Phase 3 results for a competing lung disease drug.
Source:Oct 12, 2026, 10:55 UTC
BRISTOL MYERS SQUIBB CO announced positive topline results from the interim Phase 3 ACTION-1 analysis of RYZ101 in patients with GEP-NETs.
Oct 12, 2026, 10:50 UTC
BRISTOL MYERS SQUIBB CO reported that its Phase III ALOFT-IPF trial of admilparant in adults with idiopathic pulmonary fibrosis met its primary endpoint.
Oct 12, 2026, 10:50 UTC
BRISTOL MYERS SQUIBB CO said a study met its primary endpoint.
Source:Oct 8, 2026, 22:00 UTC
The UK government will invest £33 million through the Dame Barbara Windsor Dementia Goals programme to support dementia research and clinical-trial recruitment.
Source:Oct 8, 2026, 22:00 UTC
The UK government will announce a £48 million partnership with healthcare companies and charities to accelerate dementia research and development.
Oct 8, 2026, 16:27 UTC
BRISTOL MYERS SQUIBB CO announced topline results from its Phase 3 EXCALIBER-RRMM study of Zenbexus, reporting a 51% reduction in blood cancer progression risk.
Source:Oct 8, 2026, 10:59 UTC
BRISTOL MYERS SQUIBB CO announced that ZENBEXUS (iberdomide) combined with daratumumab and dexamethasone demonstrated superior progression-free survival versus an unspecified comparator.
Source:Sep 30, 2026, 21:32 UTC
The U.S. Food and Drug Administration approved an expanded indication for Bristol Myers Squibb's CAMZYOS (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults and pediatric patients.
Source:Sep 30, 2026, 10:26 UTC
China's National Medical Products Administration granted conditional approval via priority review for Bristol-Myers Squibb Pharma EEIG's Class 1 innovative drug ibodutamide hydrochloride capsules (brand name Zanfu) for treating adults with multiple myeloma who have received at least one prior line of therapy.
Sep 23, 2026, 22:00 UTC
Bristol Myers Squibb confirmed 265 additional layoffs in New Jersey on a rolling basis starting in December, bringing its 2026 New Jersey layoffs to 718 workers as part of a plan to trim $2 billion by 2027.
Source:Sep 23, 2026, 17:45 UTC
AbbVie, Astex Pharmaceuticals, Bristol Myers Squibb, Johnson & Johnson, and Takeda jointly trained the federated AI model AISB-1-Fed on more than 20,000 proprietary protein–ligand structures in collaboration with Columbia University's AlQuraishi lab, achieving 52.1% high-quality interface predictions versus 35.6% for OpenFold3 Preview 2 and 40.9% for Boltz-2.
Source:Sep 21, 2026, 20:17 UTC
Travere Therapeutics appointed Bradley L. Campbell as President and Chief Executive Officer effective December 1, 2026.
Sep 21, 2026, 11:06 UTC
SystImmune, a wholly owned subsidiary of Sichuan Biokin Pharmaceutical, triggered the second $250 million near-term contingent payment under its global strategic collaboration with Bristol Myers Squibb for iza-bren (BL-B01D1) after the global Phase III IZABRIGHT-Lung02 trial reached a milestone.
Source:Sep 18, 2026, 10:59 UTC
Bristol Myers Squibb announced it will report its third-quarter 2026 results on October 29, 2026.
Sep 17, 2026, 22:45 UTC
Bristol Myers Squibb (BMY) shares closed at $62.84, down 1.19% from the previous trading session.
Source:Sep 17, 2026, 20:17 UTC
Faeth Therapeutics, Inc. appointed Dr. Karen Vousden as a Class II director and member of its Compensation Committee, effective September 11, 2026, with an option grant of 25,000 shares under the 2026 Equity Incentive Plan.
Sep 17, 2026, 10:59 UTC
Bristol Myers Squibb presented two-year data showing durable efficacy and consistent safety of Sotyktu (deucravacitinib) in adults with psoriatic arthritis.
Source:
Page 1Next →